American Oriental Bioengineering, Inc. (AOBI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2012 | -39.63 Million USD | -612.71% |
| 2011 | -48.77 Million USD | -79.46% |
| 2010 | 43.25 Million USD | -40.69% |
| 2009 | 72.7 Million USD | -26.32% |
| 2008 | 72.21 Million USD | 72.21% |
| 2007 | 56.97 Million USD | 44.67% |
| 2006 | 39.09 Million USD | 94.39% |
| 2005 | 19.58 Million USD | 73.08% |
| 2004 | 10.84 Million USD | 64.04% |
| 2003 | 7.33 Million USD | 145.67% |
| 2002 | 2.74 Million USD | 8339.32% |
| 2001 | 1.82 Million USD | 94.98% |
| 2000 | -712.03 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2013 Q1 | -14.58 Million USD | -510.85% |
| 2013 Q3 | -15.96 Million USD | -115.2% |
| 2013 Q2 | -7.41 Million USD | 49.14% |
| 2012 Q1 | -12.29 Million USD | 27.06% |
| 2012 FY | - USD | -612.71% |
| 2012 Q4 | 3.55 Million USD | 121.61% |
| 2012 Q3 | -16.43 Million USD | 20.16% |
| 2012 Q2 | -20.58 Million USD | -67.41% |
| 2011 Q4 | -16.85 Million USD | -315.2% |
| 2011 FY | - USD | -79.46% |
| 2011 Q3 | 7.83 Million USD | -21.1% |
| 2011 Q2 | 9.92 Million USD | 20.71% |
| 2011 Q1 | 8.22 Million USD | -12.07% |
| 2010 Q2 | 10.67 Million USD | 11.5% |
| 2010 Q3 | 12.15 Million USD | 13.8% |
| 2010 Q4 | 9.35 Million USD | -23.04% |
| 2010 Q1 | 9.57 Million USD | -53.25% |
| 2010 FY | - USD | -40.69% |
| 2009 Q2 | 21.51 Million USD | 64.56% |
| 2009 FY | - USD | -26.32% |
| 2009 Q4 | 20.48 Million USD | 18.92% |
| 2009 Q1 | 13.07 Million USD | -67.03% |
| 2009 Q3 | 17.22 Million USD | -19.93% |
| 2008 FY | - USD | 72.21% |
| 2008 Q1 | 14.41 Million USD | -33.76% |
| 2008 Q4 | 39.65 Million USD | 64.91% |
| 2008 Q3 | 24.04 Million USD | 12.67% |
| 2008 Q2 | 21.33 Million USD | 48.0% |
| 2007 Q3 | 14.96 Million USD | 21.12% |
| 2007 Q4 | 21.76 Million USD | 45.43% |
| 2007 Q1 | 8.73 Million USD | -40.95% |
| 2007 FY | - USD | 44.67% |
| 2007 Q2 | 12.35 Million USD | 41.41% |
| 2006 Q4 | 14.8 Million USD | 45.76% |
| 2006 FY | - USD | 94.39% |
| 2006 Q3 | 10.15 Million USD | 28.18% |
| 2006 Q2 | 7.92 Million USD | 12.9% |
| 2006 Q1 | 7.01 Million USD | 3.86% |
| 2005 Q4 | 6.75 Million USD | 30.97% |
| 2005 Q1 | 3.58 Million USD | -33.2% |
| 2005 Q2 | 5.03 Million USD | 40.36% |
| 2005 Q3 | 5.15 Million USD | 2.45% |
| 2005 FY | - USD | 73.08% |
| 2004 Q3 | 2.75 Million USD | 37.78% |
| 2004 Q2 | 2 Million USD | 15.41% |
| 2004 Q1 | 1.73 Million USD | -26.62% |
| 2004 FY | - USD | 64.04% |
| 2004 Q4 | 5.36 Million USD | 94.69% |
| 2003 Q4 | 2.41 Million USD | 35.56% |
| 2003 Q1 | 1.56 Million USD | 263.74% |
| 2003 Q2 | 1.61 Million USD | -2.13% |
| 2003 Q3 | 1.73 Million USD | 13.12% |
| 2003 FY | - USD | 145.67% |
| 2002 Q3 | 458.05 Thousand USD | -58.09% |
| 2002 Q1 | 1.01 Million USD | -100.0% |
| 2002 FY | - USD | 8339.32% |
| 2002 Q4 | 733.52 Thousand USD | -2.28% |
| 2002 Q2 | 540.03 Thousand USD | 0.0% |
| 2001 Q2 | -35.52 Thousand USD | 10.99% |
| 2001 FY | - USD | 94.98% |
| 2001 Q4 | 14.63 Thousand USD | -64.8% |
| 2001 Q3 | 41.58 Thousand USD | 217.03% |
| 2001 Q1 | -39.91 Thousand USD | -34.45% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | -332.55 Thousand USD | 0.0% |
| 2000 Q2 | -75.78 Thousand USD | 77.21% |
| 2000 Q3 | -274 Thousand USD | -261.55% |
| 2000 Q4 | -29.68 Thousand USD | 89.16% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 44.202% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -568.535% |
| SQZ Biotechnologies Company | -64.14 Million USD | 38.204% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -128.191% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 142.15% |
| Mesoblast Limited | -62.38 Million USD | 36.469% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -2480.442% |
| Genus plc | 73.7 Million USD | 153.781% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -499.512% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -1017.476% |
| Marizyme, Inc. | -34.28 Million USD | -15.622% |
| ContraFect Corporation | -64.99 Million USD | 39.019% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -351.857% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -775.721% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -2727.553% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -1398.871% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -1605.677% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -7551.224% |
| Accustem Sciences Inc. | -3.74 Million USD | -957.993% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 17.812% |
| EV Biologics, Inc. | -1.26 Million USD | -3028.076% |
| Q BioMed Inc. | -617.62 Thousand USD | -6317.594% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 1209.654% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -6167.628% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -1635.043% |
| Biomind Labs Inc. | -1.03 Million USD | -3731.318% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 501.305% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -453.489% |
| Skye Bioscience, Inc. | -13.54 Million USD | -192.576% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -2564.82% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -158447.432% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -920.432% |
| IMV Inc. | -35.52 Million USD | -11.58% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -149.764% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -1484.231% |
| GB Sciences, Inc. | -1.41 Million USD | -2691.554% |
| Alpha Cognition Inc. | -9.7 Million USD | -308.392% |
| HST Global, Inc. | -5303.00 USD | -747342.165% |
| CSL Limited | 4.78 Billion USD | 100.828% |
| Halberd Corporation | -74.27 Thousand USD | -53262.132% |
| Enzolytics Inc. | -2.12 Million USD | -1767.875% |
| Resverlogix Corp. | -11.74 Million USD | -237.565% |
| Affymax, Inc. | -14.29 Million USD | -177.278% |
| SYBLEU INC | -141.57 Thousand USD | -27897.865% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -1194.047% |
| argenx SE | -216.02 Million USD | 81.652% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 28.374% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 3356.932% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -2544.386% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 10562.58% |
| AVAX Technologies, Inc. | -6.11 Million USD | -548.441% |
| Zenith Capital Corp. | -8.6 Million USD | -360.572% |
| Genscript Biotech Corporation | -248.71 Million USD | 84.064% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -227423.437% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -1520.171% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -22417.825% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -1270.415% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -3688.245% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 589583.314% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -2164.965% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -1963.441% |
| BioStem Technologies, Inc. | -7.55 Million USD | -424.738% |
| ONE Bio Corp. | 13.61 Million USD | 391.168% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -21788.175% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -1826.926% |
| Agentix Corp. | -1.37 Million USD | -2789.498% |
| LadRx Corporation | 412.28 Thousand USD | 9713.993% |
| Cell Source, Inc. | -4.27 Million USD | -827.715% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -10693.734% |
| Regen BioPharma, Inc. | 1.46 Million USD | 2803.823% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -4130.418% |
| NovAccess Global Inc. | -1.03 Million USD | -3730.399% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 547.682% |
| Itoco Inc. | -1.86 Million USD | -2020.758% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -10341.193% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -3451.69% |
| Kadimastem Ltd | -2.62 Million USD | -1410.332% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -16474.057% |
| CytoDyn Inc. | -18.02 Million USD | -119.851% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -50054.827% |
| Mobile Lads Corp. | -2.24 Million USD | -1668.588% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -324021.825% |
| Qrons Inc. | -40.08 Thousand USD | -98791.889% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -8061.139% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 7615.051% |
| Rebus Holdings, Inc. | -951 Thousand USD | -4067.914% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -3632.249% |
| International Stem Cell Corporation | 202 Thousand USD | 19722.207% |
| Bioxytran, Inc. | -3.82 Million USD | -937.574% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -75197.983% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -1509.99% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -10.504% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -87981.907% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -1347.657% |
| Neutra Corp. | -181.24 Thousand USD | -21768.973% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -96.621% |
| PureTech Health plc | -11.62 Million USD | -240.904% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -96.635% |
| IXICO plc | -707 Thousand USD | -5506.345% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -415.769% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 18.014% |
| CSL Limited | 4.73 Billion USD | 100.837% |
| Cellectis S.A. | -92.63 Million USD | 57.212% |